' 
SCIENTIFIC SCORE
Questionable
Based on 19 Researches
6.7
USERS' SCORE
Good
Based on 1 Review
8.5
Supplement Facts
Serving Size: 1 Vegetable Capsule
Amount Per Serving
%DV
Vitamin D3 (as cholecalciferol)
125 mcg (5000 IU)
625%
Top Medical Research Studies
7
Vitamin D's role in heart health
The Impact of Vitamin D Deficiency on Coronary Artery Disease Severity Based on Myocardial Perfusion Imaging: A Cross-Sectional Study.
Direct focus on heart disease
We examined how low levels of vitamin D (Vit D) could impact the severity of heart disease, specifically looking at myocardial ischemia. Our study involved two hundred patients who underwent myocardial perfusion imaging at Namazi Hospital in Shiraz, Iran, in 2019. We assessed both the severity of ischemia in patients and their vitamin D levels.
The results revealed a clear pattern: when vitamin D levels dropped below 10 ng/mL, patients showed a significant increase in severe myocardial ischemia. Conversely, in patients with higher levels of vitamin D, we did not find any substantial association with abnormalities in heart imaging. This indicates that maintaining adequate vitamin D levels may play a role in reducing heart disease severity.
Overall, our findings suggest that vitamin D deficiency, especially levels below 10 ng/mL, could contribute to more severe heart conditions. This could prompt health care providers to consider monitoring and addressing vitamin D levels in patients at risk for heart disease.
The results revealed a clear pattern: when vitamin D levels dropped below 10 ng/mL, patients showed a significant increase in severe myocardial ischemia. Conversely, in patients with higher levels of vitamin D, we did not find any substantial association with abnormalities in heart imaging. This indicates that maintaining adequate vitamin D levels may play a role in reducing heart disease severity.
Overall, our findings suggest that vitamin D deficiency, especially levels below 10 ng/mL, could contribute to more severe heart conditions. This could prompt health care providers to consider monitoring and addressing vitamin D levels in patients at risk for heart disease.
Read More
8
Vitamin D's impact on heart hypertrophy
Contributing role and molecular basis of Vitamin D/Vitamin D receptor deficiency in hyperhomocysteinemia-induced cardiac hypertrophy.
Significant relevance in heart disease
We explored the relationship between vitamin D deficiency and heart disease, particularly how it interacts with a condition called hyperhomocysteinemia, which is known to promote heart issues. In our study, we examined both animal models (rats fed a diet to induce hyperhomocysteinemia) and heart cells under lab conditions to understand this interaction better.
Our findings revealed that hyperhomocysteinemia significantly lowered levels of vitamin D, specifically 1,25(OH)D, in the blood and heart tissues. We also noted an increase in the expression of an enzyme (CYP24A1) that breaks down vitamin D, indicating a disruption in its availability. Moreover, the presence of elevated homocysteine was linked to a decrease in vitamin D receptor (VDR) expression in heart tissues, complicating the heart's ability to respond to vitamin D’s effects.
By manipulating levels of VDR, we demonstrated that reducing VDR led to more heart cell growth, which is a sign of heart hypertrophy. Conversely, when VDR was overexpressed, we observed a decrease in hypertrophy, showing that vitamin D plays a protective role against heart enlargement during hyperhomocysteinemia. Additionally, a specific microRNA (miR-125b-5p) was found to repress VDR and contribute to heart cell growth, highlighting the complex regulatory network involved.
Our study concluded that vitamin D deficiency and reduced VDR contribute to heart issues associated with high levels of homocysteine by activating harmful cellular pathways. This underscores the potential significance of monitoring and supporting vitamin D levels, especially in individuals suffering from hyperhomocysteinemia.
Our findings revealed that hyperhomocysteinemia significantly lowered levels of vitamin D, specifically 1,25(OH)D, in the blood and heart tissues. We also noted an increase in the expression of an enzyme (CYP24A1) that breaks down vitamin D, indicating a disruption in its availability. Moreover, the presence of elevated homocysteine was linked to a decrease in vitamin D receptor (VDR) expression in heart tissues, complicating the heart's ability to respond to vitamin D’s effects.
By manipulating levels of VDR, we demonstrated that reducing VDR led to more heart cell growth, which is a sign of heart hypertrophy. Conversely, when VDR was overexpressed, we observed a decrease in hypertrophy, showing that vitamin D plays a protective role against heart enlargement during hyperhomocysteinemia. Additionally, a specific microRNA (miR-125b-5p) was found to repress VDR and contribute to heart cell growth, highlighting the complex regulatory network involved.
Our study concluded that vitamin D deficiency and reduced VDR contribute to heart issues associated with high levels of homocysteine by activating harmful cellular pathways. This underscores the potential significance of monitoring and supporting vitamin D levels, especially in individuals suffering from hyperhomocysteinemia.
Read More
8
Vitamin D improves heart health
The Effect of Vitamin D Deficiency Treatment on Lipid Profile and C-reactive Protein in Patients with Ischemic Heart Disease: Double-blind Randomized Clinical Trial.
Study shows vitamin D benefits
We conducted a double-blind, randomized clinical trial to explore how treating vitamin D deficiency affects heart health, specifically in patients with ischemic heart disease (IHD). In our study, we involved 44 patients aged between 40 and 65 who were dealing with low vitamin D levels. They were divided into two groups—one receiving vitamin D supplements and the other a placebo.
Over five weeks, patients in the intervention group received weekly doses of 50,000 units of vitamin D. We measured changes in their lipid profiles, which includes important markers like cholesterol and triglycerides, as well as C-reactive protein (CRP), an indicator of inflammation.
Our findings revealed that vitamin D supplementation led to significant improvements. Patients in the intervention group showed an increase in good cholesterol (HDL) and a decrease in triglycerides, which are both beneficial for heart health. While the placebo group also experienced some minor improvements, the notable changes were primarily in the group receiving vitamin D.
Overall, these results suggest that addressing vitamin D deficiency can have positive effects on lipid levels in IHD patients. This is an encouraging insight for healthcare providers looking to manage heart disease risk more effectively.
Over five weeks, patients in the intervention group received weekly doses of 50,000 units of vitamin D. We measured changes in their lipid profiles, which includes important markers like cholesterol and triglycerides, as well as C-reactive protein (CRP), an indicator of inflammation.
Our findings revealed that vitamin D supplementation led to significant improvements. Patients in the intervention group showed an increase in good cholesterol (HDL) and a decrease in triglycerides, which are both beneficial for heart health. While the placebo group also experienced some minor improvements, the notable changes were primarily in the group receiving vitamin D.
Overall, these results suggest that addressing vitamin D deficiency can have positive effects on lipid levels in IHD patients. This is an encouraging insight for healthcare providers looking to manage heart disease risk more effectively.
Read More
Most Useful Reviews
8.3
Improved ejection fraction
D3 assisted in improving my ejection fraction after heart disease surgery. I took 10,000 units daily for six months. My doctor claimed I would never raise my ejection fraction without beta blockers, but I managed to return it to normal using D3 and 300 mg of ubiquinol each day.
Read More
Medical Researches
SCIENTIFIC SCORE
Questionable
Based on 19 Researches
6.7
- All Researches
8
Vitamin D3 and SGLT2i synergy explored
Unveiling the benefits of Vitamin D3 with SGLT-2 inhibitors for hypertensive obese obstructive sleep apnea patients.
Combined treatment benefits assessed
We conducted a study to explore how vitamin D3, combined with SGLT2 inhibitors, could influence heart health in hypertensive obese patients suffering from obstructive sleep apnea (OSA). This combination therapy was assessed for its effects on various health parameters and the quality of life of the participants.
In our investigation, patients were randomly assigned to receive either Dapagliflozin, vitamin D3, a combination of both, or no treatment at all over 16 weeks. We closely looked at measurements such as weight, blood pressure, blood sugar levels, liver health, and heart function among others.
Our findings were promising, revealing beneficial effects of combining vitamin D3 with SGLT2 inhibitors. Participants who received this combination reported improvements in their cardio-metabolic health and overall quality of life, suggesting a potential new approach to managing heart disease in this specific group of patients.
It is important to note that while this study highlights the synergistic benefits of vitamin D3 and SGLT2 inhibitors, the isolated impact of vitamin D itself on heart disease remains somewhat unclear. This complexity underscores the need for further research to fully understand vitamin D's role in cardiovascular health.
In our investigation, patients were randomly assigned to receive either Dapagliflozin, vitamin D3, a combination of both, or no treatment at all over 16 weeks. We closely looked at measurements such as weight, blood pressure, blood sugar levels, liver health, and heart function among others.
Our findings were promising, revealing beneficial effects of combining vitamin D3 with SGLT2 inhibitors. Participants who received this combination reported improvements in their cardio-metabolic health and overall quality of life, suggesting a potential new approach to managing heart disease in this specific group of patients.
It is important to note that while this study highlights the synergistic benefits of vitamin D3 and SGLT2 inhibitors, the isolated impact of vitamin D itself on heart disease remains somewhat unclear. This complexity underscores the need for further research to fully understand vitamin D's role in cardiovascular health.
Read More
8
Vitamin D's impact on heart hypertrophy
Contributing role and molecular basis of Vitamin D/Vitamin D receptor deficiency in hyperhomocysteinemia-induced cardiac hypertrophy.
Significant relevance in heart disease
We explored the relationship between vitamin D deficiency and heart disease, particularly how it interacts with a condition called hyperhomocysteinemia, which is known to promote heart issues. In our study, we examined both animal models (rats fed a diet to induce hyperhomocysteinemia) and heart cells under lab conditions to understand this interaction better.
Our findings revealed that hyperhomocysteinemia significantly lowered levels of vitamin D, specifically 1,25(OH)D, in the blood and heart tissues. We also noted an increase in the expression of an enzyme (CYP24A1) that breaks down vitamin D, indicating a disruption in its availability. Moreover, the presence of elevated homocysteine was linked to a decrease in vitamin D receptor (VDR) expression in heart tissues, complicating the heart's ability to respond to vitamin D’s effects.
By manipulating levels of VDR, we demonstrated that reducing VDR led to more heart cell growth, which is a sign of heart hypertrophy. Conversely, when VDR was overexpressed, we observed a decrease in hypertrophy, showing that vitamin D plays a protective role against heart enlargement during hyperhomocysteinemia. Additionally, a specific microRNA (miR-125b-5p) was found to repress VDR and contribute to heart cell growth, highlighting the complex regulatory network involved.
Our study concluded that vitamin D deficiency and reduced VDR contribute to heart issues associated with high levels of homocysteine by activating harmful cellular pathways. This underscores the potential significance of monitoring and supporting vitamin D levels, especially in individuals suffering from hyperhomocysteinemia.
Our findings revealed that hyperhomocysteinemia significantly lowered levels of vitamin D, specifically 1,25(OH)D, in the blood and heart tissues. We also noted an increase in the expression of an enzyme (CYP24A1) that breaks down vitamin D, indicating a disruption in its availability. Moreover, the presence of elevated homocysteine was linked to a decrease in vitamin D receptor (VDR) expression in heart tissues, complicating the heart's ability to respond to vitamin D’s effects.
By manipulating levels of VDR, we demonstrated that reducing VDR led to more heart cell growth, which is a sign of heart hypertrophy. Conversely, when VDR was overexpressed, we observed a decrease in hypertrophy, showing that vitamin D plays a protective role against heart enlargement during hyperhomocysteinemia. Additionally, a specific microRNA (miR-125b-5p) was found to repress VDR and contribute to heart cell growth, highlighting the complex regulatory network involved.
Our study concluded that vitamin D deficiency and reduced VDR contribute to heart issues associated with high levels of homocysteine by activating harmful cellular pathways. This underscores the potential significance of monitoring and supporting vitamin D levels, especially in individuals suffering from hyperhomocysteinemia.
Read More
8
Vitamin D improves heart health
The Effect of Vitamin D Deficiency Treatment on Lipid Profile and C-reactive Protein in Patients with Ischemic Heart Disease: Double-blind Randomized Clinical Trial.
Study shows vitamin D benefits
We conducted a double-blind, randomized clinical trial to explore how treating vitamin D deficiency affects heart health, specifically in patients with ischemic heart disease (IHD). In our study, we involved 44 patients aged between 40 and 65 who were dealing with low vitamin D levels. They were divided into two groups—one receiving vitamin D supplements and the other a placebo.
Over five weeks, patients in the intervention group received weekly doses of 50,000 units of vitamin D. We measured changes in their lipid profiles, which includes important markers like cholesterol and triglycerides, as well as C-reactive protein (CRP), an indicator of inflammation.
Our findings revealed that vitamin D supplementation led to significant improvements. Patients in the intervention group showed an increase in good cholesterol (HDL) and a decrease in triglycerides, which are both beneficial for heart health. While the placebo group also experienced some minor improvements, the notable changes were primarily in the group receiving vitamin D.
Overall, these results suggest that addressing vitamin D deficiency can have positive effects on lipid levels in IHD patients. This is an encouraging insight for healthcare providers looking to manage heart disease risk more effectively.
Over five weeks, patients in the intervention group received weekly doses of 50,000 units of vitamin D. We measured changes in their lipid profiles, which includes important markers like cholesterol and triglycerides, as well as C-reactive protein (CRP), an indicator of inflammation.
Our findings revealed that vitamin D supplementation led to significant improvements. Patients in the intervention group showed an increase in good cholesterol (HDL) and a decrease in triglycerides, which are both beneficial for heart health. While the placebo group also experienced some minor improvements, the notable changes were primarily in the group receiving vitamin D.
Overall, these results suggest that addressing vitamin D deficiency can have positive effects on lipid levels in IHD patients. This is an encouraging insight for healthcare providers looking to manage heart disease risk more effectively.
Read More
8
Vitamin D3 shows potential heart protection
Electrocardiographic, biochemical, and scintigraphic evidence for the cardioprotective effect of paricalcitol and vitamin D3 on doxorubicin-induced acute cardiotoxicity in rats.
Study details vitamin D3 usage
We explored the effects of vitamin D3 and paricalcitol on heart health, particularly in the context of doxorubicin-induced cardiotoxicity. In our study, we worked with male Wistar rats divided into various groups, some receiving doxorubicin, a drug known for its heart-damaging potential. Others were treated with vitamin D3 or paricalcitol, both thought to have protective qualities against heart injury.
After administering doxorubicin, we observed significant changes in a range of biochemical markers and physiological indicators, including ECG readings and scintigraphy results. The findings suggested that both vitamin D3 and paricalcitol demonstrate potential cardioprotective effects by reducing inflammation and oxidative stress linked to heart damage.
This study shines a light on the possible benefits of vitamin D3 in protecting the heart during chemotherapy treatments. However, readers should note that while our findings are promising, they stem from an animal model, and further research is needed to confirm these effects in humans.
After administering doxorubicin, we observed significant changes in a range of biochemical markers and physiological indicators, including ECG readings and scintigraphy results. The findings suggested that both vitamin D3 and paricalcitol demonstrate potential cardioprotective effects by reducing inflammation and oxidative stress linked to heart damage.
This study shines a light on the possible benefits of vitamin D3 in protecting the heart during chemotherapy treatments. However, readers should note that while our findings are promising, they stem from an animal model, and further research is needed to confirm these effects in humans.
Read More
8
Vitamin D3 offers cardiac protection
Cardioprotective effect of vitamin D3 on cisplatin-induced cardiotoxicity in male mice: role of oxidative stress.
Study highlights vitamin D3 benefits.
We examined how vitamin D3 could play a role in protecting the heart from damage caused by cisplatin, a chemotherapy drug. In our research, we worked with male Balb-c mice, dividing them into several groups to evaluate different treatment approaches. Some groups received vitamin D3 before or after cisplatin injection, while others acted as controls.
Our findings revealed that cisplatin significantly raised markers indicating heart damage and increased oxidative stress levels. In contrast, when we administered vitamin D3, whether as a preventive measure or treatment after cisplatin exposure, it showed promising results. It was able to improve heart tissue structure and biochemical indicators associated with heart injury, suggesting that vitamin D3 may mitigate some of the cardiac risks linked with chemotherapy.
However, while vitamin D3 showed a protective effect in the groups that received it before cisplatin treatment, the benefits were only partial when given afterward. This highlights the potential of vitamin D3 in supporting heart health during cancer treatment, although more research is necessary to understand its full capabilities and best applications.
Our findings revealed that cisplatin significantly raised markers indicating heart damage and increased oxidative stress levels. In contrast, when we administered vitamin D3, whether as a preventive measure or treatment after cisplatin exposure, it showed promising results. It was able to improve heart tissue structure and biochemical indicators associated with heart injury, suggesting that vitamin D3 may mitigate some of the cardiac risks linked with chemotherapy.
However, while vitamin D3 showed a protective effect in the groups that received it before cisplatin treatment, the benefits were only partial when given afterward. This highlights the potential of vitamin D3 in supporting heart health during cancer treatment, although more research is necessary to understand its full capabilities and best applications.
Read More
User Reviews
USERS' SCORE
Good
Based on 1 Review
8.5
- All Reviews
- Positive Reviews
- Negative Reviews
8.3
Improved ejection fraction
D3 assisted in improving my ejection fraction after heart disease surgery. I took 10,000 units daily for six months. My doctor claimed I would never raise my ejection fraction without beta blockers, but I managed to return it to normal using D3 and 300 mg of ubiquinol each day.
